Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841212 | 0.90 | SOS1 (0.50) | SOS1POLBPKMALDH1A1KMT2A | |
| SCHEMBL11957620 | 0.82 | SOS1 (0.64) | SOS1POLBPKMALDH1A1KMT2A | |
| SCHEMBL1844573 | 0.81 | SOS1 (0.59) | SOS1POLBPKMKMT2A | |
| SCHEMBL11957617 | 0.80 | SOS1 (0.60) | SOS1POLBPKMALDH1A1KMT2A | |
| SCHEMBL1838065 | 0.79 | SOS1 (0.59) | SOS1POLBPKMALDH1A1KMT2A | |
| SCHEMBL11957619 | 0.78 | SOS1 (0.58) | SOS1POLBPKMALDH1A1KMT2A | |
| SCHEMBL1842102 | 0.77 | IKBKB (0.41) | POLBTDP1 | |
| SCHEMBL1844372 | 0.77 | LMNA (0.47) | ALDH1A1L3MBTL1ITGB1ITGA4 | |
| SCHEMBL11957622 | 0.77 | IKBKB (0.40) | SOS1POLBADORA2ATDP1 | |
| SCHEMBL15497760 | 0.73 | SOS1 (1.00) | SOS1POLBPKMALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | claimed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2321281-A2 | ANTI INFLAMMATORY COMPOUNDS | Elder Pharmaceuticals Ltd (IN) | 2011-05-18 | — | — | EP | claimed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | IL1B, LITAF, IL6 | SOS1 3516/4885POLB 1587/4885PKM 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.